19 annotations
Excluding COVID testing-related sales and the U.S. sales impacted by the temporary manufacturing shutdown, total Abbott sales increased 6% on an organic basis in the third quarter.
Foreign exchange had an unfavorable year-over-year impact of 6% on third quarter sales.
(No comment added)
Transcript
2022 Q3
24 Oct 22
organic sales growth was negatively impacted by a temporary shutdown of manufacturing at our nutrition plant in Sturgis, Michigan
(No comment added)
Transcript
2022 Q3
24 Oct 22
sales increased 1.3% on an organic basis in the quarter. COVID testing-related sales were $1.7 billion
(No comment added)
Transcript
2022 Q3
24 Oct 22
we increased our full year adjusted earnings per share guidance to $5.17 to $5.23, which is more than 10% higher than the initial guidance flow we provided back in January
(No comment added)
Transcript
2022 Q3
24 Oct 22
Some of the FX as we go forward also will be a headwind.
(No comment added)
Transcript
2022 Q3
24 Oct 22
the impact of inflation and supply chain and some of the back orders that we encountered was a headwind.
(No comment added)
Transcript
2022 Q3
24 Oct 22
the inventory that we purchased and manufacture this year at these higher costs will definitely negatively impact us next year when that inventory is sold, even if inflationary pressures start to come down kind of as we get into next year.
(No comment added)
Transcript
2022 Q3
24 Oct 22
we have seen a little bit of moderation in the rate of increase in the third quarter compared to where we were earlier in the year
(No comment added)
Transcript
2022 Q3
24 Oct 22
On inflation, definitely, we are seeing the impacts there. Like others the biggest impacts we have seen is really around commodities, other manufacturing input cost and logistics.
We have incorporated about another $100 million impact to gross margin in our current guidance.
So that’s about $1 billion for the year, so call it, maybe 240, probably, a little more than 240 basis points on the gross margin.
(No comment added)
Transcript
2022 Q3
24 Oct 22
our full year headwind is a little bit more than $0.15 in terms of earnings. About $0.10 of that is happening just in the fourth quarter alone
FX impact
Transcript
2022 Q3
24 Oct 22
I don’t think that anybody right now as we are planning going into next year is forecasting that this is just going to ease up, right? So, specifically, I would say probably inflation, I don’t expect to get better
(No comment added)
Transcript
2022 Q3
24 Oct 22
Diabetes Care, because we believe this is a $10 billion franchise by 2028
(No comment added)
Transcript
2022 Q3
24 Oct 22
We forecast COVID testing-related sales of approximately $500 million, which does not assume a COVID testing surge in the fourth quarter.
(No comment added)
Transcript
2022 Q3
24 Oct 22
We forecast total company organic sales growth, excluding the impact of COVID testing-related sales to be in the mid-single digits for the fourth quarter.
(No comment added)
Transcript
2022 Q3
24 Oct 22
per share guidance of $0.86 to $0.92 for the fourth quarter
(No comment added)
Transcript
2022 Q3
24 Oct 22
for the full year, we now forecast ongoing earnings per share of $5.17 to $5.23
(No comment added)
Transcript
2022 Q3
24 Oct 22
impacts of the nutrition manufacturing disruption and inflation we have experienced on certain manufacturing and distribution costs across our businesses.
(No comment added)
Transcript
2022 Q3
24 Oct 22
global supply chain dynamics, staffing shortages continued to impact our healthcare markets, though we are seeing steady signs of improvements.
(No comment added)
Transcript
2022 Q3
24 Oct 22
Inflation continues to be a stubborn force globally, but we have started to see some moderating impacts in certain areas of our businesses compared to earlier in the year.
(No comment added)
Transcript
2022 Q3
24 Oct 22
- Prev
- 1
- Next